Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X about a paper by Ruben Raychaudhuri et al. published in European Urology:
“Neoadjuvant pembrolizumab (×3) plus accelerated MVAC (×4, q2w) in nonurothelial MIBC
Ph2, single-arm: pCR 53%, downstaging 59%, 2-yr EFS 64%, OS 79%. Grade 3 AEs 47%, no Tx-related deaths. Mostly cT2 (59%) and cN0 (94%), rare and aggressive subtypes.”
Title: Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial
Authors: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, Kelsey K. Baker, Kevin Ng, Xueyan Chen, Jenny Mao, Brianna Woo, Aaron Lin, Andrii Hannochka, Nathan Conrad, Martha Kahugu, Patrick Panlasigui, Michael C. Haffner, Andrew C. Hsieh, Hung-Ming Lam, Funda Vakar-Lopez, Todd Yezefski, Michael T. Schweizer, Robert B. Montgomery, Evan Y. Yu, Atreya Dash, Sarah P. Psutka, Daniel W. Lin, George R. Schade, John L. Gore, Jonathan L. Wright, Petros Grivas
You can read the Full Article on European Urology.
More posts featuring Oscar Tahuahua.
